Vetter Pharma

Vetter Pharma, headquartered in Germany and operating in the Surgical and Medical Instrument Manufacturing industry, has disclosed its carbon emissions and climate commitments.

For the year 2025, Vetter Pharma reported Scope 1 emissions of approximately 18,779,000 kg CO2e. This includes about 415,810 kg CO2e from mobile combustion, 477,190 kg CO2e from fugitive emissions, and 17,031,440 kg CO2e from stationary combustion. Additionally, Scope 3 emissions for 2025 were approximately 496,085,000 kg CO2e. Key categories within Scope 3 include about 175,841,290 kg CO2e from capital goods, 269,420,530 kg CO2e from purchased goods and services, and 18,940,340 kg CO2e from upstream transportation and distribution.

In 2024, the company's Scope 1 emissions were approximately 16,986,000 kg CO2e, and Scope 3 emissions were about 393,795,000 kg CO2e. For 2023, Scope 1 emissions stood at approximately 17,852,000 kg CO2e, with Scope 3 emissions at about 271,087,000 kg CO2e. In 2022, Vetter Pharma reported Scope 1 emissions of approximately 18,000,000 kg CO2e and Scope 3 emissions of about 408,611,000 kg CO2e. In 2021, Scope 1 emissions were around 19,683,000 kg CO2e, and Scope 3 emissions were approximately 217,431,000 kg CO2e. No Scope 2 emissions data was disclosed for any of these years.

Vetter Pharma has set ambitious climate commitments, with near-term Science Based Targets initiative (SBTi) validated targets. The company commits to reducing absolute Scope 1 and Scope 2 GHG emissions by 58.8% by 2034, against a 2021 base year. Furthermore, Vetter Pharma aims to achieve net-zero emissions across all scopes by 2050. They also plan for 80% of their suppliers by spend, covering purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by 2029.